Skip to main content
OpenTrials
Completed

NCT Number: NCT06361875

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

The purpose of this study was to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) [adults ≥ 65 years of age only], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Immunization Healthy Volunteers Infections Influenza, Human Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Investigational Site Number : 3400001, San Pedro Sula, Honduras

Loading trial locations.

About this study

Study duration per participant was approximately 12 months.

  • Treatment duration: 1 injection of one of the 7 QIV mRNA or one of the controls
  • Dose escalation with sequential enrollment

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged from 18 years on the day of inclusion or aged from 21 years on the days of inclusion, depending on the countries.
  • A female participant was eligible to participate if she was not pregnant or breastfeeding and one of the following conditions applied:
  • Was of non-childbearing potential. To be considered of non-childbearing potential, a female must of been postmenopausal for at least 1 year, or surgically sterile OR
  • Was of childbearing potential and agreed to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration.
  • A female participant of childbearing potential must of had a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the 1st dose of study intervention

Exclusion criteria

Participants were excluded from the study if any of the following criteria applied:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA vaccine
  • Previous history of myocarditis, pericarditis, and / or myopericarditis
  • Known history of previous episodes of Gillian-Barre Syndrome (GBS), neuritis (including Bell's palsy), convulsions, encephalitis, transverse myelitis, and vasculitis
  • Participants with an ECG that is consistent with possible myocarditis or pericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results
  • Self-reported thrombocytopenia, contraindicating Intramuscular vaccination based on Investigator's judgment
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating Intramuscular vaccination based on Investigator's judgment
  • Chronic illness that, in the opinion of the Investigator, was at a stage where it might have interfered with study conduct or completion
  • Moderate or severe acute illness / infection (according to Investigator's judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of vaccination. A prospective participant was not included in the study until the condition was resolved or the febrile event subsided
  • Participant who had acute infection symptoms or a positive SARS-CoV-2 RT-PCR or antigen test in the past 10 days prior to the 1st visit (V01)
  • Receipt of any vaccine in the 4 weeks preceding study intervention administration or planned receipt of any vaccine in the 4 weeks following study intervention administration
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine
  • Receipt of any mRNA vaccine/product in the 2 months preceding study intervention administration

NOTE: The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Treatment and study plan

Quadrivalent Influenza mRNA Vaccine MRT5421

Biological

Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

Quadrivalent Influenza mRNA Vaccine MRT5424

Biological

Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection

Quadrivalent Influenza mRNA Vaccine MRT5429

Biological

Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection

Quadrivalent Influenza Standard Dose Vaccine

Biological

Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection

Other names: Fluzone Qudrivalent®

Quadrivalent Influenza High-Dose Vaccine

Biological

Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection

Other names: Fluzone High-Dose Quadrivalent®

Quadrivalent Recombinant Influenza Vaccine

Biological

Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection

Other names: Flublok Quadrivalent®

Primary outcomes

  1. Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) After Vaccine Administration

    Time frame: Within 30 minutes after vaccine administration on Day 1

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions, that is, pre-listed in the case report form in terms of diagnosis and onset window post-vaccination. Systemic AEs are all AEs that were not injection or administration site reactions. Immediate events are recorded to capture medically relevant unsolicited systemic AEs which occur within the first 30 minutes after vaccination.

  2. Number of Participants With Solicited Injection Site Reactions After Vaccine Administration

    Time frame: Within 7 days after vaccine administration on Day 1

    An adverse reaction (AR) is any noxious and unintended response to a study vaccine related to any dose. Solicited injection site reactions are reactions at and around the injection site of the vaccine observed and reported under the conditions (nature and onset) pre-listed in the protocol and case report form.

  3. Number of Participants With Solicited Systemic Reactions After Vaccine Administration

    Time frame: Within 7 days after vaccine administration on Day 1

    An AR is any noxious and unintended response to a study vaccine related to any dose. Solicited systemic reactions are systemic AEs observed and reported under the conditions (nature and onset) pre-listed in the protocol and case report form.

  4. Number of Participants With Unsolicited Adverse Events After Vaccine Administration

    Time frame: Within 28 days after vaccine administration on Day 1

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions, that is, pre-listed in the case report form in terms of diagnosis and onset window post-vaccination.

  5. Number of Participants With Medically Attended Adverse Events (MAAEs)

    Time frame: Within 180 days after vaccine administration on Day 1

    An MAAE is a new onset or a worsening of a condition that prompts the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department.

  6. Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)

    Time frame: From the vaccine administration (Day 1) until 12 months after vaccine administration, approximately 366 days

    An SAE is any untoward medical occurrence that at any dose results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event. An AESI (serious or non-serious) is 1 of scientific and medical concern specific to the Sponsor's study vaccine or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor can be appropriate. The AESIs was defined as anaphylactic reactions (including bronchospasms, and laryngeal spasms), Guillain-Barré syndrome, neuritis (including Bell's palsy), myocarditis, pericarditis, myopericarditis and vasculitis.

  7. Number of Participants With Abnormal Biological Test Results

    Time frame: Within 8 days after vaccine administration on Day 1

    Blood samples were collected for the assessment of abnormal hematology and clinical chemistry parameters. Only participants with outside the normal range hematology and clinical chemistry parameters are reported.

  8. Geometric Mean of Hemagglutination Inhibition (HAI) Antibody (Ab) Titer at Day 1

    Time frame: Day 1

    The HAI Ab was measured by hemagglutinin inhibition using quality control sera (sheep, ferret and/or human sera) measurement method. The 95% confidence interval (CI) was based on the Clopper-Pearson method.

  9. Geometric Mean of Hemagglutination Inhibition Antibody Titer at Day 29

    Time frame: Day 29

    The HAI Ab was measured by hemagglutinin inhibition using quality control sera (sheep, ferret and/or human sera) measurement method. The 95% CI was based on the Clopper-Pearson method.

  10. Percentage of Participants With Detectable Hemagglutination Inhibition Antibody Titer >=1:10 at Day 1

    Time frame: Day 1

    The HAI Ab was measured by hemagglutinin inhibition using quality control sera (sheep, ferret and/or human sera) measurement method. The 95% CI for the single percentage was based on the Clopper-Pearson method. The percentages are rounded off to the tenth decimal place.

  11. Percentage of Participants With Detectable Hemagglutination Inhibition Antibody Titer >=1:10 at Day 29

    Time frame: Day 29

    The HAI Ab was measured by hemagglutinin inhibition using quality control sera (sheep, ferret and/or human sera) measurement method. The 95% CI for the single percentage was based on the Clopper-Pearson method. The percentages are rounded off to the tenth decimal place.

  12. Geometric Mean Ratio of Hemagglutination Inhibition Antibody Titer at Day 29

    Time frame: Days 1 and 29

    The HAI Ab was measured by hemagglutinin inhibition using quality control sera (sheep, ferret and/or human sera) measurement method. The geometric mean ratio of antibody titer at post-vaccination over pre-vaccination is reported. The 95% CI was based on the Clopper-Pearson method.

  13. Percentage of Participants With Seroconversion of Hemagglutination Inhibition Antibody Titer at Day 29

    Time frame: Day 29

    The seroconversion was defined as titer <10 on Day 1 and post-injection titer >=40 on Day 29; or defined as titer >=10 on Day 1 and a >=4-fold increase in titer on Day 29. The 95% CI for the single percentage was based on the Clopper-Pearson method. The percentages are rounded off to the tenth decimal place.

  14. Percentage of Participants With Hemagglutination Inhibition Antibody Titer >=1:40 at Day 29

    Time frame: Day 29

    The HAI Ab was measured by hemagglutinin inhibition using quality control sera (sheep, ferret and/or human sera) measurement method. The 95% CI for the single percentage was based on the Clopper-Pearson method. The percentages are rounded off to the tenth decimal place.

  15. Percentage of Participants With >=2 and >=4 Fold Increase in Hemagglutination Inhibition Antibody Titer at Day 29

    Time frame: Days 1 and 29

    The HAI Ab was measured by hemagglutinin inhibition using quality control sera (sheep, ferret and/or human sera) measurement method. The 95% CI for the single percentage was based on the Clopper-Pearson method. The percentages are rounded off to the tenth decimal place.

Secondary outcomes

  1. Geometric Mean of Neutralization Test (NT) Antibody Titer at Days 1 and 29

    Time frame: Days 1 and 29

    The NT Ab was planned to be measured using seroneutralization (SN) measurement method. The 95% CI was planned to be calculated using the Clopper-Pearson method.

  2. Geometric Mean Ratio of Neutralization Test Antibody Titer at Day 29

    Time frame: Days 1 and 29

    The NT Ab was planned to be measured using SN measurement method. The geometric mean ratio of antibody titer at post-vaccination over pre-vaccination was planned to be reported. The 95% CI was planned to be calculated using the Clopper-Pearson method.

  3. Percentage of Participants With >=2 and >=4 Fold Increase in Neutralization Test Antibody Titer at Day 29

    Time frame: Days 1 and 29

    The NT Ab was planned to be measured using SN measurement method. The 95% CI for the single percentage was planned to be calculated using the Clopper-Pearson method.

Sponsors and collaborators

Lead sponsor

Sanofi Pasteur, a Sanofi Company

Industry

Registry information

Official study title

A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 12, 2024
Registry last updated
Aug 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.